Stock ABUS ARBUTUS BIOPHARMA CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Arbutus Biopharma Corporation

Equities

ABUS

CA03879J1003

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-22 pm EDT 		5-day change 1st Jan Change
2.64 USD -2.94% Intraday chart for Arbutus Biopharma Corporation -11.11% +5.60%
Apr. 05 Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit MT
Apr. 04 Moderna Suffers Setback in Lawsuit by Arbutus MT

Evolution of the average Target Price on Arbutus Biopharma Corporation

Price target over the last 5 years

History of analyst recommendation changes

f3d1260cc0ffd92db851ab7e.10bUmD187j2T8Po_swQSqF0ABQBnPnfhPLQqLwrS39E.gALty1Esl3f_t5t0yW0h5hxYaWQBeEDWSfxaWlKIsInjLOfXRBXdUfqUzg~f2a5fdfb3b492ea46168f0034c48e8bf

Analyst Recommendations on Arbutus Biopharma Corporation

HC Wainwright Trims Price Target on Arbutus Biopharma to $5 From $6, Keeps Buy Rating MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $4 From $6, Maintains Market Outperform Rating MT
HC Wainwright Adjusts Price Target on Arbutus Biopharma to $6 From $7.50, Maintains Buy Rating MT
JMP Securities Adjusts Arbutus Biopharma Price Target to $9 From $10, Maintains Market Outperform Rating MT
HC Wainwright Adjusts Arbutus Biopharma's Price Target to $8.50 From $8, Maintains Buy Rating MT
Chardan Research Adjusts Arbutus Biopharma's Price Target to $6 From $5.50; Buy Rating Kept MT
Jefferies Upgrades Arbutus Biopharma to Buy From Hold, Adjusts Price Target to $5 From $4 MT
HC Wainwright Adjusts Arbutus Biopharma PT to $8 From $10, Maintains Buy Rating MT
JMP Securities Adjusts Price Target on Arbutus Biopharma to $9 From $7, Maintains Market Outperform Rating MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Price Target on Arbutus Biopharma to $6 From $7, Keeps Outperform Rating MT
ARBUTUS BIOPHARMA : Jefferies Starts Arbutus Biopharma at Hold With $5 Price Target MT
ARBUTUS BIOPHARMA : HC Wainwright Starts Arbutus Biopharma at Buy With $10 Price Target MT
ARBUTUS BIOPHARMA : Wedbush Adjusts Arbutus Biopharma's Price Target to $7 From $5 Following Updated AB-729 Data, Keeps at Outperform MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
3.624 CAD
Average target price
5.962 CAD
Spread / Average Target
+64.51%
High Price Target
6.786 CAD
Spread / Highest target
+87.26%
Low Price Target
5.407 CAD
Spread / Lowest Target
+49.20%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Arbutus Biopharma Corporation

HC Wainwright
JMP Securities
Chardan Research
Jefferies & Co.

Ratings for Arbutus Biopharma Corporation

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ABUS Stock
  4. Consensus Arbutus Biopharma Corporation